Progyny's Q2 2026 Call: Seasonality Claims and Progyny Select Revenue Signals Don't Match

Date of Call: Aug 6, 2026

Financials Results

• Revenue: Q2 revenue was closer to the higher end of guidance, reflecting a 5.3% increase on a reported basis and 11% excluding a large former client transition from 2025. For full-year 2026, projected revenue is between $1.36B and $1.385B, representing 5.5% to 7.5% growth.
• EPS: Q2 adjusted EPS is projected between $0.50 and $0.52. Full-year 2026 adjusted EPS is projected between $1.26 and $1.32 per diluted share.
• Gross Margin: Gross margin expanded 180 basis points YOY in Q2, comparable to the expansion seen in Q1.
• Operating Margin: Adjusted EBITDA margin expanded from the year-ago period but at a lesser rate than gross margin. Trailing 12-month adjusted EBITDA margin was 17.2%.

Guidance:

• Q3 2026 revenue expected between $335M and $345M, reflecting growth of 6.9% to 10.1%.
• Full-year 2026 revenue projected between $1.36B and $1.385B, representing 5.5% to 7.5% growth (9.7% to 11.7% excluding a prior year client transition).
• Q3 adjusted EBITDA expected between $56M and $59M.
• Full-year 2026 adjusted EBITDA projected between $233M and $240M.
• Full-year 2026 net income expected between $104.8M and $109.9M.
• Expect continued strong cash flow generation and plan for capital investments to taper starting in 2027.

Business Commentary:

Strong Financial Performance and Growth:

• Progeny, Inc. reported record quarterly revenue, gross profit, and adjusted EBITDA, with a 5.3% reported and 11% adjusted revenue increase year-over-year.
• The growth was driven by solid performance over the past several years, allowing for investment in business expansion while returning value to shareholders through share repurchases.

Momentum in Sales and Client Retention:

• Early commitments for new sales are pacing meaningfully ahead of the same period last year, with the company confident in meeting its annual target of adding 1 million or more new lives.
• Strong client retention and early decision-making by employers were driven by a focus on cost control and quality management, with Progeny's solutions being seen as a proven method to manage rising medical costs.

Seasonal Impact on ART Cycles:

• The company observed a more pronounced seasonal slowdown in ART cycles during the summer months, impacting third-quarter revenue guidance.
• This seasonality is attributed to typical patterns in member engagement and scheduling, with no long-term trend change indicated.

Gross Margin Expansion and Investment:

• Progeny's gross margin expanded by 180 basis points year-over-year, due to efficiencies in care management and a reduction in stock compensation expense.
• Investments in platform expansion and feature enhancements are continuing, with expectations for these investments to taper down starting in 2027.

Cash Flow and Share Repurchases:

• The company generated more than $50 million in operating cash flow for the fourth consecutive quarter, achieving a 75% conversion of adjusted EBITDA to operating cash flow.
• Strong cash flow allowed for continued share repurchases, with 1.2 million shares purchased under the latest program in the second quarter alone.

Sentiment Analysis:

Overall Tone: Positive

• Management reported a 'strong second quarter' with 'record quarterly revenue, gross profit, and adjusted EBITDA' and 'solid growth over the prior year period.' They expressed being 'well-positioned' for growth with 'meaningful momentum in the market' and are 'comfortable that we've positioned ourselves exceptionally well to meet our traditional target of adding one million or more new lives.'

Q&A:

• Question from Brian Tankila (Jefferies): Expand further on the ART cycle seasonality slowdown, what drove the increased seasonality, when it peaks, and when normal trends return?
  Response: The more pronounced seasonality in Q3 is limited to the middle of summer and is not seen as prolonged or a change in trend; visibility into September suggests engagement will return to normal levels for the remainder of the year.

• Question from Jalendra Singh (Truist Securities): What additional data points or observations support the view that this is seasonal softness, and not a broader trend?
  Response: Historical data shows similar seasonality patterns in the summer, with engagement returning to normal levels afterward; current visibility for September supports this normalization.

• Question from Michael Churney (Lyrinc): How did improved visibility and forecasting play out given the seasonal softness?
  Response: Visibility and forecasting algorithms have improved, but the seasonality this year was more pronounced than anticipated; overall, the adjustment to guidance is modest.

• Question from Sarah James (Cantor Fitzgerald): What is the confidence level in the forecasting algorithm for different time horizons?
  Response: Confidence is high given improved algorithms, but inherent uncertainty exists for periods further out, as demonstrated by a modest 1% adjustment to the midpoint forecast.

• Question from Scott Schoenhaus (KeyBank): Is the summer softness different than expected in any specific cohort or regional?
  Response: The softness is broad-based across cohorts, new wins, and regions, with no single pronounced factor; it is more of a general, more pronounced seasonality event.

Contradiction Point 1

Characterization of Summer Seasonality

Different statements on whether the pattern is "typical" or "more pronounced."

Brian Tankila (Jefferies) - Brian Tankila (Jefferies)

2026Q2: The more pronounced summer seasonality this year is not unusual and has been observed in past years. It is a normal pattern that typically resolves in September. - [Pete Inefsky](CEO)

Could you elaborate on the ART cycle seasonality, including factors driving the increased seasonality, its peak timing, and when normal trends are expected to return? - Brian Tanquilut (Jefferies)

2026Q2: This summer's seasonality is viewed as a typical, temporary seasonal pattern and not a prolonged trend change. - [Mark Livingston](CFO)

Contradiction Point 2

Impact of Progyny Select on 2027 Revenue

Contradiction on whether Progyny Select is expected to contribute meaningfully in 2027.

Peter Warrendorff (Barclays) - Peter Warrendorff (Barclays)

2026Q2: A good pipeline is building for next year... Progyny Select is not expected to be a meaningful revenue contributor in 2027. - [Mark Livingston](CFO)

Can you provide an update on membership trends, the impact of weaker employment, guidance assumptions, and visibility into next year’s million-lives target including Progeny Select’s contribution? - Peter Warendorf (Barclays)

2026Q2: There is a solid pipeline build for next year's selling season... It's too early to reiterate the 1 million target clarity, but the pipeline is encouraging. - [Pete Anevski](CEO)

Contradiction Point 3

Nature and Impact of Seasonal Softness

Contradiction on whether summer softness is a normal, broad-based pattern or linked to specific external factors.

Brian Tankila (Jefferies) - Brian Tankila (Jefferies)

2026Q2: The more pronounced summer seasonality this year is not unusual and has been observed in past years. It is a normal pattern that typically resolves in September. - [Pete Inefsky](CEO)

Can you expand further on the comments about ART cycle seasonality, including what drove the increased seasonality, when it will peak, and when normal trends will return? - Jailendra Singh (Truist Securities)

2026Q1: The bigger point is that the number of opportunities from current competitors is already higher than all of last year. - [Mark Livingston](CFO)

Contradiction Point 4

Growth and Expectations for the Progeny Select Channel

Contradiction on the timeline and materiality of revenue contribution from the Progeny Select channel.

Peter Warrendorff (Barclays) - Peter Warrendorff (Barclays)

2026Q2: Select is not expected to be a meaningful revenue contributor in 2027. Focus is on building channel relationships first. - [Mark Livingston](CFO)

Are membership trends flat or slightly up, what impact are weaker employment trends having, what are the assumptions in guidance for membership, what visibility exists for next year’s million-lives target, and how much will come from Progeny Select? - David Larsen (BTIG)

2026Q1: The reception is positive. The company is signing up aggregators and distributors. However, meaningful pull-through contribution is not expected until later in the year when smaller employers typically make their buying decisions. - [Pete Anevski](CEO)

Contradiction Point 5

Membership and Utilization Outlook

Contradiction on whether membership is stable or implies replacement of lower-yielding lives.

Peter Warrendorff (Barclays) - Peter Warrendorff (Barclays)

2026Q2: Lives are stable, with minor changes from small clients. No material impact from broader employment trends. - [Mark Livingston](CFO)

What are the current membership trends, the impact of weaker employment trends, and the assumptions in guidance for membership? - Jailendra Singh (Truist Securities)

20260227-2025 Q4: The adjustment relates to previously existing clients... The changes are due to administrative updates... these updates are not always perfect. - [Mark Livingston](CFO)